Seminars in Radiation Oncology
Volume 19, Issue 3 , Pages 171-178 , July 2009

Molecular Advances of Brain Tumors in Radiation Oncology

  • Shin-ei Noda, MD, PhD

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
    • ,
  • Areej El-Jawahri, MD

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
    • ,
  • Disha Patel, BA

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
    • ,
  • Tim Lautenschlaeger, MD

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
    • ,
  • Michael Siedow, BS

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
    • ,
  • Arnab Chakravarti, MD

      Affiliations

    • Department of Radiation Oncology, The Ohio State University Medical School, Columbus, OH
    • Corresponding Author InformationAddress reprint request to Arnab Chakravarti, MD, Department of Radiation Oncology, The Ohio State University Medical School, 300 W. 10th Ave., Room 080B, Columbus, Ohio 43210

References 

  1. CBTRUS. Statistical report: Primary brain tumors in the United States, 1998-2002. Chicago, IL: CBTRUS; 2006;
  2. Louis DN, Ohgaki H, Wiestler OD, et al. WHO classification of tumours of the central nervous system. (ed 4). IARC, Lyon: World Health Organization; 2007;
  3. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06. Int J Radiat Oncol Biol Phys. 1998;40:51–55
  4. Sijben AE, McIntyre JB, Roldán GB, et al. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol. 2008;89:97–103
  5. Brandes AA, Vastola F, Basso U, et al. A prospective study on glioblastoma in the elderly. Cancer. 2003;97:657–662
  6. Combs SE, Wagner J, Bischof M, et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys. 2008;70:987–992
  7. Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88:97–103
  8. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996
  9. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190–198
  10. Fine HA, Dear KBG, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585–2597
  11. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol. 2004;31:635–644
  12. Carpentier AF. Neuro-oncology: The growing role of chemotherapy in glioma. Lancet Neurol. 2005;4:4–5
  13. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466
  14. Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther. 2006;6:1087–1104
  15. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64:479–489
  16. Burger PC, Vogel FS, Green SB, et al. Glioblastoma multiforme and anaplastic astrocytoma (Pathologic criteria and prognostic implications). Cancer. 1985;56:1106–1111
  17. Ichimura K, Bolin MB, Goike HM, et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. 2000;60:417–424
  18. von Deimling A, Fimmers R, Schmidt MC, et al. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol. 2000;59:544–558
  19. Buschges R, Weber RG, Actor B, et al. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol. 1999;9:435–442
  20. Schmidt EE, lchimura K, Reifenberger G, et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 1994;54:6321–6324
  21. Reifenberger G, Reifenberger J, Ichimura K, et al. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res. 1994;54:4299–4303
  22. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: From concept to clinical diagnosis. J Neuro Oncol. 1999;1:44–51
  23. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and metal-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011–1018
  24. Fine HA, Dear KB, Loeffler JS, et al. Metaanalysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585–2597
  25. Barrie M, Couprie C, Dufour H, et al. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of highgrade astrocytoma: A Medical Research Council trial. J Clin Oncol. 2001;19:509–518
  26. Gerson SL. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4:296–307
  27. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003
  28. Sathornsumetee S, Reardon DA, Desjardins A, et al. Molecularly targeted therapy for malignant glioma. Cancer. 2007;110:13–24
  29. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res. 2006;12:4738–4746
  30. Wedge SR, Porteous JK, Glaser MG, et al. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs. 1997;8:92–97
  31. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003;63:4009–4016
  32. Wachsberger PR, Burd R, Marero N, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res. 2005;11:835–842
  33. Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol. 2007;61:153–161
  34. Eller JL, Longo SL, Kyle MM, et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery. 2005;56:155–162
  35. Geng L, Shinohara ET, Kim D, et al. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys. 2006;64:263–271
  36. Wang CC, Liao YP, Mischel PS, et al. HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. Cancer Res. 2006;66:6756–6762
  37. Goldbrunner RH, Bendszus M, Wood J, et al. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery. 2004;55:426–432
  38. van Rijn J, Heimans JJ, van den Berg J, et al. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys. 2000;47:779–784
  39. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683–2710
  40. Reifenberger G, Louis DN. Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol. 2003;62:111–126
  41. Knobbe CB, Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 2003;13:507–518
  42. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004;22:1926–1933
  43. Folkman J. Angiogenesis: An organizing principle for drug discovery?. Nat Rev Drug Discov. 2007;6:273–286
  44. Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: A review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys. 2004;58:927–931
  45. Krishnan S, Brown PD, Ballman KV, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys. 2006;65:1192–1199
  46. Kesari S, Ramakrishna N, Sauvageot C, et al. Targeted molecular therapy of malignant gliomas. Curr Neurol Neurosci Rep. 2005;5:186–197
  47. Benjamin R, Capparella J, Brown A. Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J. 2003;9:82–90
  48. Huang HJS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997;272:2927–2935
  49. Wong AJ, Bigner SH, Bigner DD, et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987;84:6899–6903
  50. Sugawa N, Ekstrand AJ, James CD, et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A. 1990;87:8602–8606
  51. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. J Neuro Oncol. 2006;8:67–78
  52. Rich JN, Reardon DA, Peery T, et al. phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:133–142
  53. Raizer JJ, Abrey LE, Wen P, et al. A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant glioma not on EIAEDs. Proc Am Soc Clin Oncol. 2004;22:1502
  54. van den Bent MJ, Brandes A, Rampling R, et al. Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26,034. Proc Am Soc Clin Oncol. 2007;25:2005
  55. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25:2288–2294
  56. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012–2024
  57. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97:880–887
  58. Lassman AB, Rossi MR, Razier JR, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium trials 01-03 and 00-01. Clin Cancer Res. 2005;11:7841–7850
  59. Chakravarti A, Berkey B, Robins HI, et al. An update of phase II results from RTOG 0211: A phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. Proc Am Soc Clin Oncol. 2006;24:1527
  60. Schwer AL, Damek DM, Kavanagh BD, et al. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2008;70:993–1001
  61. Combs SE, Heeger S, Haselmann R, et al. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (Gert)—Phase I/II trial: Study protocol. BMC Cancer. 2006;6:133
  62. Sampson JH, Archer GE, Bigner DD, et al. Heimberger Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Proc Am Soc Clin Oncol. 2008;26:2011
  63. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000;60:5143–5150
  64. Butowski NA, Chang S, Page M. Phase I/II study of enzastaurin (ENZ) plus temozolomide (TMZ) and radiation therapy (XRT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS). Proc Am Soc Clin Oncol. 2008;26:3559
  65. Feldkamp MM, Lau N, Roncari L, et al. Isotype-specific ras (GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of ras mutational status). Cancer Res. 2001;61:4425–4431
  66. Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and antiangiogenic effects. Oncogene. 1999;18:7514–7526
  67. Gilbert MR, Hess K, Gaupp P, et al. A phase I study of temozolomide and the farnesyltransferase inhibitor, tipifarnib in recurrent glioblastoma: A dose and schedule intensive regimen. J Neurooncol. 2004;6:
  68. Brandes AA, Stupp R, Hau P, et al. EORTC Study: 26041-22041: Phase I/II study on concomitant and adjuvant zemozolomide (TMZ) and tadiotherapy with or without PTK787/ZK 222584 (PTK/ZK) in newly diagnosed glioblastoma: Results of phase I. Proc Am Soc Clin Oncol. 2007;25:2026
  69. de Bouard S, Herlin P, Christensen JG, et al. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. J Neurooncol. 2007;9:412–423
  70. Jane EP, Premkumar DR, Pollack IF. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther. 2006;319:1070–1080
  71. Chaskis C, Sadones J, Michotte A, et al. A phase II trial of sunitinib in patients with recurrent high-grade glioma. Proc Am Soc Clin Oncol. 2008;26:13001
  72. Wuthrick EJ, Curran WJ, Werner-Wasik M, et al. A phase I trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. J Clin Oncol. 2008;26:2053
  73. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: Mediators and therapeutic targets. Endothelium. 2006;13:113–135
  74. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol. 2007;25:1637–1638
  75. Stupp R, Goldbrunner R, Neyns B, et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma. Proc Am Soc Clin Oncol. 2007;25:2000
  76. Zhang Y, Adachi M, Zou H, et al. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int J Radiat Oncol Biol Phys. 2006;65:859–866
  77. Zhang Y, Adachi M, Zhao X, et al. Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino-methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer. 2004;110:301–308
  78. Camphausen K, Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 2004;64:316–321
  79. Camphausen K, Cerna D, Scott T, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer. 2005;114:380–386
  80. Munshi A, Tanaka T, Hobbs ML, et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther. 2006;5:1967–1974
  81. Munshi A, Kurland JF, Nishikawa T, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res. 2005;11:4912–4922
  82. Goudar RK, Keir ST, Bigner DD, et al. NMDA and AMPA glutamate receptor antagonists in the treatment of human malignant glioma xenografts. Proc Am Assoc Cancer Res. 2004;45:1053–1054
  83. Grossman AS, Ye X, Chamberlain MC, et al. Fine phase II trial of talampanel in conjunction with standard radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM). Proc Am Soc Clin Oncol. 2008;26:2014
  84. McMurry TB. MGMT inhibitors—the Trinity College-Paterson Institute experience, a chemist's perception. DNA Repair (Amst). 2007;6:1161–1169
  85. Singh SK, Hawkins C, Clark ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401
  86. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760
  87. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related ‘self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26:3015–3024

PII: S1053-4296(09)00022-8

doi: 10.1016/j.semradonc.2009.02.005

Seminars in Radiation Oncology
Volume 19, Issue 3 , Pages 171-178 , July 2009

Article Tools

* Image Usage & Resolution